If your company is interested in proposing a compound for a EUnetHTA rapid REA on a pharmaceutical technology, please contact the Pharmaceutical Joint Production team via:
After an initial discussion on the Joint Assessment process, the next step is to complete a Letter of Intent, in which further details about the suggested compound are described: population, intervention, comparator and outcomes. The letter can be accessed at this link:
Finally, the Letter of Intent is submitted to the team at the same WP4_Pharmaceuticals@zinl.nl team address.
Please note that a Joint Assessment on your suggested compound will only be performed if sufficient EUnetHTA partners are interested in working on this topic, since one of the aims of EUnetHTA is to ensure high uptake of EUnetHTA assessments in European Member States.
Once the Joint Assessment is started, you are requested to submit a dossier. To do so, please see the following links in which you can download and consult the submission requirements and templates required for the process:
We are happy to explain the Pharmaceutical Joint Assessment process in further detail. As such, we have provided an extensive FAQ list for Pharmaceuticals that we strongly recommend first checking. For any further queries, the WP4 Team will be pleased to be of assistance.
Please access the Pharmaceuticals FAQ here.